semler scientific inc k mar    am  seeking alphasign in  join nowgo»semler scientific inc smlrform k  current reportmar    amabout semler scientific inc smlrview as pdf semler scientific inc form k received         united states securities and exchange commission washington dc        form k       current report pursuant to section  or d of the securities exchange act of    date of report date of earliest event reported march         semler scientific inc exact name of registrant as specified in its charter       delaware       state or other jurisdiction of incorporation   commission file number   irs employer identification no    nw everett st portland oregon    address of principal executive offices   zip code   registrants telephone number including area code         check the appropriate box below if the form k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions  see general instruction a below   ¨ written communications pursuant to rule  under the securities act  cfr    ¨ soliciting material pursuant to rule a under the exchange act  cfr a   ¨ precommencement communications pursuant to rule db under the exchange act  cfr db   ¨ precommencement communications pursuant to rule ec under the exchange act  cfr ec             item  results of operations and financial condition   on march   semler scientific inc issued a press release announcing its financial results for the fourth quarter and year ended december   a copy of the press release is furnished as exhibit  to this form k   the information contained in this item  and in the accompanying exhibit  shall not be deemed filed for purposes of section  of the securities exchange act of  as amended or incorporated by reference in any filing under the exchange act or the securities act of  as amended except as shall be expressly set forth by specific reference in such filing   item  financial statements and exhibits   the information contained in this item  and in the accompanying exhibit  shall not be deemed filed for purposes of section  of the securities exchange act of  as amended or incorporated by reference in any filing under the exchange act or the securities act of  as amended except as shall be expressly set forth by specific reference in such filing   d exhibits   exhibit no   description    press release of semler scientific inc dated march           signatures   pursuant to the requirements of the securities exchange act of  as amended the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized     semler scientific inc         by sdouglas murphychutorian     name douglas murphychutorian     title chief executive officer   date march           exhibit    semler reports fourth quarter and annual  financial results   continuing to increase market penetration of its quantaflo ™ product   portland ore  – march   – semler scientific inc otcqb smlr “semler” an emerging growth company that provides technology and software solutions to improve the clinical effectiveness of healthcare providers today reported financial results for the fourth quarter and year ended december     “during the fourth quarter we continued to increase the market penetration of our quantaflo™ product which we believe is due to the clinical benefits associated with its use” said doug murphychutorian md chief executive officer of semler “our financial goal in  is to generate cash from operating activities by growing revenue controlling expenses while at the same time minimizing stockholder dilution” he added   financial results   for the three months ended december   compared to corresponding period of  semler had   · revenue of  a decrease of  compared to  primarily due to  less revenue from having deemphasized sales of the lower margin wellchec™ service which was partially offset by an increase of  or  growth from concentrating on sales of the higher margin vascular testing products eg quantaflo™ · total operating expense which includes cost of revenue of  a decrease of  compared to  primarily due to a decrease of  in stock compensation expense and a decrease of  in wellchec™ expenses · cost of revenue of  a decrease of  compared to  primarily due to the change in product mix mentioned above · net loss of  or  per share a decrease of  compared to a net loss of  or  per share   for the year ended december   compared to  semler had   · revenue of  an increase of  compared to  primarily due to an increase of  from our vascular testing products partially offset by a decrease of  from deemphasizing the lower margin wellchec™ service · total operating expense which includes cost of revenue of  a decrease of  compared to  primarily due to a decrease of  in stock compensation expense and a decrease of  in wellchec™ expenses · cost of revenue of  a decrease of  compared to  primarily due to the change in product mix mentioned above         · net loss of  or  per share a decrease of  compared to a net loss of  or  per share   for the three months ended december   compared to three months ended september   semler had   · revenue of  an increase of  or  compared to  during both of these threemonth periods revenue was solely from our vascular testing products · total operating expense which includes cost of revenue of  an increase of  compared to  · cost of revenue of  an increase of  compared to  · net loss of  or  per share a decrease of  compared to a net loss of  or  per share   as of december   compared to december   semler had · cash of  an increase of  compared to     highlights   the major accomplishments of  were as follows    increased the established base of quantaflo™ installations    migrated customers to quantaflo™ from its lowerpriced predecessor product    contracted with home risk assessment “hra” companies to use quantaflo™ in order to enhance their wellness services   in  revenue from quantaflo™ is expected to continue to grow due to an increasing number of installations higher average pricing as compared to its predecessor product and the recurring revenue business model   in  as in the second half of  semler prefers to work as a secondary vendor to its hra customers rather than be a primary vendor for its wellchec™ business wellchec™ was responsible for both substantial revenue growth and associated startup costs in  by focusing on its quantaflo™ business and being a secondary vendor for wellness services semler intends to better leverage capital have lower financial risk and require less operational expertise while potentially having a higher margin business   “ we continue to grow quantaflo ™ revenue and to reduce our net operating loss as we near profitability ” said dr murphychutorian “our immediate objective is to become the standard of care for testing to identify patients at risk for heart attacks and strokes to enable better preventive medical care  ” he added         notice of conference call   semler will host a conference call at  am et friday march th  the call will address fourth quarter and yearend results and will provide a business update on semler’s market outlook and strategies for the nearterm future   the conference call may be accessed by dialing   for domestic callers and   for international callers please specify to the operator that you would like to join the semler fourth quarter and full year  financial results call conference id  the conference call will be archived on semlers website at wwwsemlerscientificcom          semler scientific inc condensed statements of operations in thousands except share and per share amounts       for the three months ended december      for the year ended december        unaudited                                                         revenue                                                             operating expenses                                 cost of revenue                             engineering and product development                             sales and marketing                             general and administrative                                                               total operating expenses                                                               loss from operations                                                           other expense                                                           net loss                                                       net loss per share basic and diluted                                                       weighted average number of shares used in computing basic and diluted loss per share                                     semler scientific inc audited condensed balance sheets in thousands of us dollars       as of     as of       december       december                   cash             other current assets               noncurrent assets               total assets                                 current liabilities               noncurrent liabilities               stockholders deficit             total liabilities and stockholders deficit                     about semler scientific inc   semler scientific inc is an emerging growth company that provides technology and software solutions to improve the clinical effectiveness of healthcare providers our mission is to develop manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases our first patented and us food and drug administration or fda cleared product introduced commercially in  measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease in march  we received fda k clearance for the next generation version of this product named quantaflo™ which was commercially launched in august  to more comprehensively evaluate our customers’ patients for risk of heart attacks and strokes  we believe we are positioned to provide valuable information to our insurance company and physician customers which in turn permit them to better guide patient care additional information about semler can be found at semlerscientificcom    forwardlooking statements   this press release contains “forwardlooking” statements such statements can be identified by among other things the use of forwardlooking language such as the words “may” “will” “expect” “anticipate” “estimate” “project” “would” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions the forwardlooking statements in this release include statements regarding achieving profitability and cash flow from operations with minimal stockholder dilution revenue growth from quantaflo™ business as well as expected effect of shift in plans regarding wellchec™ such forwardlooking statements are subject to a number of risks and uncertainties that could cause semler scientific’s actual results to differ materially from those discussed here such as whether or not insurance plans and other customers will continue to lease its cardiovascular testing products along with those statements detailed in semler scientific’s sec filings and involve assumptions estimates and uncertainties that reflect current internal projections expectations or beliefs there can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements all forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above furthermore all such statements are made as of the date of this release and semler scientific assumes no obligation to update or revise these statements unless otherwise required by law   contact   susan a noonan sa noonan communications susansanoonancom      source  semler scientific inc        semler scientific inc private company information  bloomberg july    pm et healthcare equipment and supplies company overview of semler scientific inc snapshot people company overview semler scientific inc develops manufactures and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the united states its products include quantaflo a fourminute inoffice blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition and wellchec a multitest service platform that performs tests for various chronic diseases such as respiratory disease vascular disease eye disease bone disease heart disease neuropathy and diabetes the company’s products serve cardiologists internists nephrologists endocrinologists podiatrists a semler scientific inc develops manufactures and markets patented products that assist healthcare providers to evaluate and treat patients with chronic diseases in the united states its products include quantaflo a fourminute inoffice blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition and wellchec a multitest service platform that performs tests for various chronic diseases such as respiratory disease vascular disease eye disease bone disease heart disease neuropathy and diabetes the company’s products serve cardiologists internists nephrologists endocrinologists podiatrists and family practitioners as well as organizations including healthcare insurance plans integrated delivery networks independent physician groups and companies contracting with the healthcare industry and other healthcare organizations such as risk assessment groups and other home healthcare providers it offers its products through salespersons and distributors semler scientific inc was founded in  and is based in portland oregon detailed description  nw everett streetportland or united statesfounded in  employees phone  semlerscientificcom key executives for semler scientific inc dr douglas murphychutorian md chief executive officer president and director age  total annual compensation k mr daniel e conger principal accounting officer and vice president of finance age  total annual compensation k mr robert g mcrae chief technical officer age  total annual compensation k mr james m walker consultant age  total annual compensation k compensation as of fiscal year  semler scientific inc key developments semler scientific inc reports unaudited earnings results for the first quarter ended march   may   semler scientific inc reported unaudited earnings results for the first quarter ended march   for the period the company’s revenue was  compared to  a year ago loss from operations was  against  a year ago net loss was  or  per basic and diluted share compared to  or  per basic and diluted share a year ago semler scientific inc to report q  results on may   apr   semler scientific inc announced that they will report q  results at  am eastern standard time on may   semler scientific inc q  earnings call may   apr   semler scientific inc q  earnings call may   similar private companies by industry company name region decimal inc united states  genesystems inc united states  imaging llc united states st century scientific inc united states x corporation united states recent private companies transactions typedate target no transactions available in the past  months request profile update   the information and data displayed in this profile are created and managed by sp global market intelligence a division of sp global bloombergcom does not create or control the content for inquiries please contact sp global market intelligence directly by clicking here stock quotes market data is delayed at least  minutes company lookup most searched private companies company name geographic region lawyers committee for civil rights under law united states nyc inc united states the advertising council inc united states bertelsmann ag europe rush university united states sponsored financial commentaries sponsored links browse companies a b c d e f g h i j k l m n o p q r s t u v w x y z              request profile update only a company representative may request an update for the company profile documentation will be required to contact semler scientific inc please visit semlerscientificcom company data is provided by sp global market intelligence please use this form to report any data issues information missing  please enter your information in the following fields company name your name your email address your phone number type of data overview executives key developments similar companies transactions update needed all data changes require verification from public sources please include the correct value or values and a source where we can verify cancel submit your requested update has been submitted our data partners will research the update request and update the information on this page if necessary research and followup could take several weeks if you have questions you can contact them at bwwebmasterbusinessweekcom close semler scientific  current report print email pdf word xls semler scientific inc form k received         united states securities and exchange commission washington dc        form k       current report pursuant to section  or d of the securities exchange act of    date of report date of earliest event reported may         semler scientific inc exact name of registrant as specified in its charter   delaware       state or other jurisdiction of incorporation   commission file number   irs employer identification no    nw everett st portland oregon    address of principal executive offices   zip code registrants telephone number including area code             check the appropriate box below if the form k filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions  see general instruction a below   ¨ written communications pursuant to rule  under the securities act  cfr    ¨ soliciting material pursuant to rule a under the exchange act  cfr a   ¨ precommencement communications pursuant to rule db under the exchange act  cfr db   ¨ precommencement communications pursuant to rule ec under the exchange act  cfr ec   indicate by check mark whether the registrant is an emerging growth company as defined in rule  of the securities act of  §  of this chapter or rule b of the securities exchange act of  § b of this chapter   emerging growth company     x   if an emerging growth company indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section a of the exchange act ¨                 item  results of operations and financial condition   on may   semler scientific inc issued a press release announcing its financial results for the fourth quarter and year ended march   a copy of the press release is furnished as exhibit  to this form k   the information contained in this item  and in the accompanying exhibit  shall not be deemed filed for purposes of section  of the securities exchange act of  as amended or incorporated by reference in any filing under the exchange act or the securities act of  as amended except as shall be expressly set forth by specific reference in such filing   item  financial statements and exhibits   the information contained in this item  and in the accompanying exhibit  shall not be deemed filed for purposes of section  of the securities exchange act of  as amended or incorporated by reference in any filing under the exchange act or the securities act of  as amended except as shall be expressly set forth by specific reference in such filing   d exhibits   exhibit no   description    press release of semler scientific inc dated may               signatures   pursuant to the requirements of the securities exchange act of  as amended the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized     semler scientific inc         by sdouglas murphychutorian     name douglas murphychutorian     title chief executive officer   date may             exhibit        semler reports first quarter  financial results   inventory and manufacturing capacity grow to prepare for larger orders   portland ore  – may   – semler scientific inc otcqb smlr an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers today reported financial results for the first quarter ended march     “we believe that our products enable our customers to identify when preventive care options are appropriate which allows them to intervene before events like heart attacks or strokes occur” said doug murphychutorian md chief executive officer of semler “hence the incentives for our customers to use our products include better clinical outcomes for their patients and better economics for their businesses” he added   financial results   for the three months ended march   compared to corresponding period of  semler had   · revenue of  an increase of  compared to  · total operating expense which includes cost of revenue of  an increase of  compared to  · cost of revenue of  an increase of  compared to  · net loss of  or  per share a decrease of  compared to a net loss of  or  per share   for the sequential three months ended march   compared to three months ended december   semler had   · revenue of  a decrease of  compared to  · total operating expense which includes cost of revenue of  an increase of  compared to  · cost of revenue of  an increase of  compared to  · net loss of  or  per share an increase of  compared to a net loss of  or  per share · cash of  a decrease of  compared to        page  of      first quarter  highlights   the major accomplishments of the first quarter were as follows    increased inventory and manufacturing capacity for our vascular testing product quantaflo™ in preparation for anticipated continued customer base growth in     received new and expanded orders for quantaflo™ which we expect to be installed in the second quarter resulting in continued sequential quarterly revenue growth as part of our recurring revenue model    migrated more customers to quantaflo™ from its lowerpriced predecessor product    developed additional cybersecurity protections that are intended to aid our customers in complying with regulations regarding safeguarding personal health information   in  revenue from quantaflo™ is expected to grow due to an increasing number of installations higher average pricing as compared to its predecessor product and the recurring revenue business models that we employ we have received new and expanded orders in the first quarter that we have installed in the second quarter of    sequential results for first quarter  compared to fourth quarter  showed some decreases due to lower revenue from our feepertest customers who primarily include home risk assessment service providers and who we believe historically conduct more business in the latter half of the calendar year than in the earlier months also in the first quarter of  operating expenses were impacted by higher expenditures such as those for increased manufacturing and fulfillment capabilities projects to improve cybersecurity measures and research and development projects   “our immediate objective is to become the standard of care for testing to identify patients at risk for heart attacks and strokes to enable better preventive medical care” said dr murphychutorian “the first quarter performance was outstanding in this regard particularly in growing our order book for fulfillment in the second quarter of   ” he concluded   notice of conference call   semler will host a conference call at  am et tuesday may   the call will address first quarter results and will provide a business update on semler’s market outlook and strategies for the nearterm future   the conference call may be accessed by dialing  for domestic callers and  for international callers please specify to the operator that you would like to join the semler first quarter  financial results call conference id  the conference call will be archived on semlers website at wwwsemlerscientificcom        page  of      semler scientific inc statements of operations in thousands of us dollars except for share and per share amounts       for the three months ended march        unaudited                             revenue                                operating expenses                 cost of revenue               engineering and product development               sales and marketing               general and administrative                                 total operating expenses                                 loss from operations                               interest and other expense             other expense             interest and other expense                               net loss                             net loss per share basic and diluted                             weighted average number of shares used in computing basic and diluted loss per share                     page  of      semler scientific inc condensed balance sheets in thousands of us dollars       as of     as of       march       december         unaudited                       cash             other current assets               noncurrent assets               total assets                                 current liabilities               noncurrent liabilities               stockholders deficit             total liabilities and stockholders deficit                   page  of      about semler scientific inc   semler scientific inc is an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers our mission is to develop manufacture and market innovative proprietary products and services that assist our customers in evaluating and treating chronic diseases our first patented and us food and drug administration or fda cleared product introduced commercially in  measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease in march  we received fda k clearance for the next generation version of this product named quantaflo™ which was commercially launched in august  to more comprehensively evaluate our customers’ patients for risk of heart attacks and strokes  we believe we are positioned to provide valuable information to our insurance company and physician customers which in turn permit them to better guide patient care additional information about semler can be found at semlerscientificcom    forwardlooking statements   this press release contains “forwardlooking” statements such statements can be identified by among other things the use of forwardlooking language such as the words “may” “will” “expect” “anticipate” “estimate” “project” “would” “could” or words with similar meaning or the negatives of these terms or by the discussion of strategy or intentions the forwardlooking statements in this release include statements regarding growth in the customer base continued revenue growth from quantaflo™ business and the effects of the company’s cybersecurity measures such forwardlooking statements are subject to a number of risks and uncertainties that could cause semler scientific’s actual results to differ materially from those discussed here such as whether or not insurance plans and other customers will continue to lease its cardiovascular testing products along with those statements detailed in semler scientific’s sec filings and involve assumptions estimates and uncertainties that reflect current internal projections expectations or beliefs there can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements all forward looking statements contained in this press release are qualified in their entirety by these cautionary statements and the risk factors described above furthermore all such statements are made as of the date of this release and semler scientific assumes no obligation to update or revise these statements unless otherwise required by law   contact   susan a noonan sa noonan communications susansanoonancom      source  semler scientific inc        page  of  analyst coverage  semler scientific home quantaflo wellchec investor info contact us investors home → investor info → analyst coverage analyst coverage zacks small cap research semler scientific is covered by the following analyst analyst coverage firm analyst zacks small cap research brian marckx cfa please note that any opinions estimates or forecasts regarding semler scientifics performance made by these analysts are theirs alone and do not represent opinions forecasts or predictions of semler scientific or its management semler scientific does not by its reference above or distribution imply its endorsement of or concurrence with such information conclusions or recommendations shareholder tools shareholder briefcase email alerts download library snapshot print share x facebook google linkedin twitter email rss site navigation home quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   copyright  semler scientific inc  privacy policy  terms of use  contact us back to top events  presentations  semler scientific home quantaflo wellchec investor info contact us investors home → investor info → events  presentations events  presentations upcoming event date event details remind me aug    am et semler scientific q  financial results email x semler scientific q  financial results email reminder please sign up for email alert notification outlook google presentations date title   semler march  presentation archived events date event details may    am et semler scientific q  financial results download mp  mb mar    am et fourth quarter and yearend  call download mp  mb  add file to briefcase shareholder tools shareholder briefcase email alerts download library snapshot print share x facebook google linkedin twitter email rss site navigation home quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   copyright  semler scientific inc  privacy policy  terms of use  contact us back to top investor info  semler scientific home quantaflo wellchec investor info contact us investors home → investor info investor info we are an emerging growth company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers our mission is to develop manufacture and market innovative proprietary products and services that assist our customers who include insurance plans physicians and risk assessment groups in evaluating and treating chronic diseases in  we began commercializing our first patented and us food and drug administration or fda cleared product which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease or pad in march  we received fda k clearance for the next generation product quantaflo™ which we began commercializing in august  in april  we launched our multitest service platform wellchec™ to more comprehensively evaluate our customers’ patients for chronic disease including heart attacks and strokes using our quantaflo™ product as well as other tests however in october  we shifted our marketing focus for wellchec™ from direct contracts with health insurance plans under which we acted as the primary wellchec™ service provider to contracts to supply our software and equipment to vendors who employ medical professionals to do annual wellness visits for health insurance plans we believe our products position us to provide valuable information to our customer base of insurance plans physicians and risk assessment companies which in turn permit them to better guide patient care intra  mo  mo  yr semler first quarter  financial results call may  am et mp press releases jul   semler to report second quarter  financial results and host conference call on august   may   semler reports first quarter  financial results view all press releases » events aug   at  am et semler scientific q  financial results presentations semler march  presentation view all events  presentations » shareholder tools shareholder briefcase email alerts download library snapshot print share x facebook google linkedin twitter email rss site navigation home quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   copyright  semler scientific inc  privacy policy  terms of use  contact us back to top investor info  semler scientific home quantaflo wellchec investor info contact us investors home → investor info investor info we are an emerging growth company providing technology solutions to improve the clinical effectiveness and efficiency of healthcare providers our mission is to develop manufacture and market innovative proprietary products and services that assist our customers who include insurance plans physicians and risk assessment groups in evaluating and treating chronic diseases in  we began commercializing our first patented and us food and drug administration or fda cleared product which measured arterial blood flow in the extremities to aid in the diagnosis of peripheral arterial disease or pad in march  we received fda k clearance for the next generation product quantaflo™ which we began commercializing in august  in april  we launched our multitest service platform wellchec™ to more comprehensively evaluate our customers’ patients for chronic disease including heart attacks and strokes using our quantaflo™ product as well as other tests however in october  we shifted our marketing focus for wellchec™ from direct contracts with health insurance plans under which we acted as the primary wellchec™ service provider to contracts to supply our software and equipment to vendors who employ medical professionals to do annual wellness visits for health insurance plans we believe our products position us to provide valuable information to our customer base of insurance plans physicians and risk assessment companies which in turn permit them to better guide patient care intra  mo  mo  yr semler first quarter  financial results call may  am et mp press releases jul   semler to report second quarter  financial results and host conference call on august   may   semler reports first quarter  financial results view all press releases » events aug   at  am et semler scientific q  financial results presentations semler march  presentation view all events  presentations » shareholder tools shareholder briefcase email alerts download library snapshot print share x facebook google linkedin twitter email rss site navigation home quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   copyright  semler scientific inc  privacy policy  terms of use  contact us back to top semler scientific inc smlrpk company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile semler scientific inc smlrpk related topics stocksstock screenerhealthcaremedical equipment supplies  distribution overview news key developments people charts financials analysts research pulse smlrpk on otc markets group usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description semler scientific inc incorporated on september   develops manufactures and markets products and services that assist healthcare insurers and physician groups in evaluating and treating chronic diseases the company markets quantaflo and wellchec to its customers quantaflo is an approximately fourminute inoffice blood flow test wellchec is the companys multitest service platform the company offers quantaflo product to cardiologists internists nephrologists endocrinologists podiatrists and family practitioners and organizations including healthcare insurance plans integrated delivery networks independent physician groups and companies contracting with the healthcare industry it offers wellchec service platform to health insurance plans and other healthcare organizationsthe companys quantaflo features a sensor clamp that is placed on the toe or finger as current pulse oximetry devices infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination returning light is sensed by the sensor a blood flow waveform is instantaneously constructed by the companys software algorithm and displayed on the video monitor both index fingers and both large toes are interrogated which takes approximately  seconds for each a hardcopy report form is generated that displays over four waveforms and the ratio of each leg measurement compared with the arms results are classified as flow obstruction or no flow obstruction the routine office usage of the quantaflo has ranges from few tests per week to over  tests per day the company also offers contracts in which it invoices on a per test basis for use of quantaflo or as part of the wellchec multitest platformquantaflo is also the centerpiece of the companys wellness diagnostic testing service wellchec wellchec provides testing equipment and thirdparty personnel to perform tests and examinations of patients for the companys customers the company invoices on a fee per test or per examination basis for this service the tests performed are for chronic disease states which include respiratory disease vascular disease eye disease bone disease heart disease neuropathy and diabetes » full overview of smlrpk company address semler scientific inc  nw everett stportland   or    p f  company web links home page officers  directors name compensation herbert semler  douglas murphychutorian  shirley semler  robert mcrae  daniel conger  » more officers  directors semler scientific inc news » more smlrpk news related topics stocksstock screenerhealthcaremedical equipment supplies  distribution financials  filings  semler scientific home quantaflo wellchec investor info contact us investors home → investor info → financials  filings financials  filings first quarter  financial results semler scientific q  financial results semler reports first quarter  financial results form q proxy statements date filed view oct   html pdf xls sep   html pdf xls form k date filed view mar   html pdf xls xbrl feb   html pdf xls xbrl form q date filed view may   html pdf xls xbrl nov   html pdf xls xbrl  add pdf file to briefcase shareholder tools shareholder briefcase email alerts download library snapshot print share x facebook google linkedin twitter email rss site navigation home quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   copyright  semler scientific inc  privacy policy  terms of use  contact us back to top stock information  semler scientific home quantaflo wellchec investor info contact us investors home → investor info → stock information stock information stock quote smlr      am et on jul   previous close  open  volume na exchange ot day high na day low na week high  week low  stock chart compare benchmark nasdaq nyse sp  amex options area graph ohlc line graph candlestick time intraday  day  month  months  months  year  years  years  years range from to   the stock information provided is for informational purposes only and is not intended for trading purposes the stock information is provided by esignal stock charts are provided by edgar online both third party services and semler scientific does not maintain or provide information directly to this service stock information is delayed approximately  minutes shareholder tools shareholder briefcase email alerts download library snapshot print share x facebook google linkedin twitter email rss site navigation home quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   copyright  semler scientific inc  privacy policy  terms of use  contact us back to top smlr key statistics  semler scientific inc financial ratios  marketwatch bulletin investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close semler scientific inc otc smlr go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus semler scientific inc market open  quotes are delayed by  min jul    pm smlr quoteszigmandelayed   change   volume volume  quotes are delayed by  min quoteszigmandelayed previous close     change   day low day high    week low  week high   company description semler scientific inc engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers it also involves in development manufacturing and marketing of proprietary products and services that assist customers in evaluating and treating chr semler scientific inc engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers it also involves in development manufacturing and marketing of proprietary products and services that assist customers in evaluating and treating chronic diseases the company was founded by herbert j semler and shirley l semler on august   and is headquartered in portland or valuation pe current  pe ratio with extraordinary items  price to sales ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  capital structure total debt to total assets  officers and executives name age officer since title dr herbert j semler   chairman dr doug r murphychutorian   president chief executive officer  director mr robert g mcrae   chief operating  technical officer mr daniel e conger   principal accounting officer  vpfinance mr dennis rosenberg   chief marketing officer insider actions – purchase – sale  – number of transactions  date name shares transaction value  herbert j semler director    derivativenonderivative trans at  per share   shirley l semler director    disposition at  per share   shirley l semler director    disposition at  per share   herbert j semler director    disposition at  per share   herbert j semler director    disposition at  per share   herbert j semler director    disposition at  per share   herbert j semler director    disposition at  per share   herbert j semler director    disposition at  per share   herbert j semler director    disposition at  per share   aidan matthew collins director    acquisition at  per share  newslatestcompanyussmlr marketwatch news on smlr no news currently available for smlr newsnonmarketwatchcompanyussmlr other news on smlr semler scientifics smlr ceo douglas murphychutorian on q  results  earnings call transcript  pm may    seeking alpha q semler scientific inc  am may    edgar online  edg  q k k semler scientific inc  pm march    edgar online  edg  q k semler scientifics smlr ceo douglas murphychutorian on q  results  earnings call transcript  pm march    seeking alpha q semler scientific inc  pm nov    edgar online  edg  q k semler scientifics smlr ceo douglas murphychutorian on q  results  earnings call transcript  am oct    seeking alpha at a glance semler scientific inc  nw everett street portland oregon  phone   industry medical equipmentsupplies sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for smlr newspressreleasecompanyussmlr press releases on smlr semler to report second quarter  financial results and host conference call on august    am july    pr newswire  prf semler reports first quarter  financial results  am may    pr newswire  prf semler to report first quarter  financial results and host conference call on may    am april    pr newswire  prf semler reports fourth quarter and annual  financial results  am march    pr newswire  prf semler to report fourth quarter and full year  financial results and host conference call on march    am feb    pr newswire  prf semler scientific recognized by deloittes technology fast ™ growth award  am nov    pr newswire  prf delisting of securities of xtera communications inc lime energy co cosi inc semler scientific inc and stereotaxis inc from the nasdaq stock market  pm nov    globenewswire semler reports third quarter and yeartodate  financial results  am oct    pr newswire  prf semler to report third quarter  financial results and host conference call on october    am oct    pr newswire  prf trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite tlt quoteszigmancomposite jnug x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest ppeople still aren’t saving for retirement — and that’s part of why myra is shutting down pto be a better investor read more good novels pact like a pro athlete the next time you ask for a pay raise pwhy gold buyers are so susceptible to fraud poil prices log biggest weekly gain of the year pgold tallies third weekly gain on north korea news weaker dollar psept wti oil climbs  cents or  to settle at bbl pwti oil ends at highest since late may up  for the week pwhat trump could do to make obamacare ‘implode’ pare you prepared for retirement  questions to ask yourself p questions to ask yourself before you buy — or sell — a house pwagerebound story takes another hit after drab eci report pstock market lower after amazon disappointment but pares losses phow a college degree is like a social security check popinion journal the trump tax reform agenda pretire early sounds great on paper but it could cost a lot p things to do in london for  or less pwho are the beneficiaries of a k if my wife and i die at the same time pcharlie gard british baby at center of controversy has died punder armours stocks low price doesnt mean it is cheap loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  home  semler scientific semler scientific inc is an emerging medical riskassessment company whose diagnostic and testing products and services help to guide patient care and close the gap between cost of care and compensation for care quantaflo™ semler scientific manufactures the quantaflo™ system leading the way in vascular disease testing wellchec™ wellchec™ is a service of semler scientific providing turnkey assessment testing throughout the us for a variety of conditions investor info latest company news press releases stock price documents sec filings events and more signup for email news alerts here site navigationhome quantaflo wellchec investors contact us press releases careers contact us semler scientific inc  bern court san jose ca   click here to contact us scroll to top bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one semler scientific  ipo candy skip to primary navigation skip to content becomeamember ipo candyeveryones favorite site for ipo insights and analysismain navigationhome » semler scientificsemler scientific  by semler scientific inc a medical riskassessment company develops manufactures and markets patented products that assist healthcare providers to monitor patients and evaluate chronic diseases in the united states its products include flochec which is used in the office setting to allow providers to measure arterial blood flow in the extremities the company provides its flochec product and services for internists and primary care physicians through its salespersons and coexclusive distributor semler scientific inc was founded in  and is headquartered in portland oregon semler scientific semler scientific inc a medical riskassessment company develops manufactures and markets patented products that assist healthcare providers to monitor patients and evaluate chronic diseases in the united states its products include flochec which is used in the office setting to allow providers to measure arterial blood flow in the extremities the company provides its flochec product and services for internists and primary care physicians through its salespersons and coexclusive distributor semler scientific inc was founded in  and is headquartered in portland oregon twitter facebook google linkedin semler scientificpsemler scientific inc a medical riskassessment company develops manufactures and markets patented products that assist healthcare providers to monitor patients and evaluate chronic diseases in the united states its products include flochec which is used in the office setting to allow providers to measure arterial blood flow in the extremities the company provides its flochec product and services for internists and primary care physicians through its salespersons and coexclusive distributor semler scientific inc was founded in  and is headquartered in portland oregonp orunited statesphone  smlr blood flow instruments documents roadshow main categoryhealthcare categoriesdevices contact httpsemlerscientificcom  address nw everett street portland oregon  united states we love ipos the ipo market provides a magical window into the most exciting technologies emerging consumer trends and important business developments  all testing their mettle in the crucible of the public markets we are constantly learning and researching to deliver the best insights available we are independent we have no vested interests driving our work all the investment banks and brokers on a deal are paid to do a sales and marketing job our job is to remain objective and use a factbased approach to evaluate the potential for an ipo we get the best ratings ipo candy has been recognized since  as the single best place to get commentary analysis and assets in the ipo market the most common writein comment we get from users is that they love what we do we share everything we know with three decades of research under our belt we want to share what we have learned and the best practices we have discovered our ipo university contains texts videos and resources to share our process and help everyone develop their skills become an ipocandy member enjoy the benefits of full access to our content including access to ipo roadshow slideshows and transcripts included in our posts members also get additional insights via email receive our monthly candygram and have access to our ipo calendar become a member semler scientific inc smlr market data  news  equitiescom breaking news previous next ​mark dubowitz from the foundation for defense of democracies on us policy toward russia ​time for convertible securities ​working with  types of global influencers automation in forex trading good or bad real estate crowdfunding when things go badly usglobal canada companies log in login to your account log in remember me forgot your password forgot your username register semler scientific inc smlr  follow trade x close by  profile semler scientific inc is a medical riskassessment company it develops manufactures  markets patented products that assist healthcare providers in monitoring patients and evaluating chronic diseases its products include quanataflo and wellchec contact information website wwwsemlerscientificcom main phone    address  nw everett street state or city  town portland country usa postal code  issuer information exchange nsc employees  naics surgical and med      d d d mo mo mo y y max last price  change   change   tick na bid na bid size na ask na ask size na open na high na low na prev close  last trade jul   volume   wk hi   wk low  market cap  mi exdiv date na div rate na yield na shares  eps ttm  pe ratio na exchange otcqb insider estimates filings analysts   last  mo last  mo number of insider trades   number of buys   number of sells   net activity   last  buys shares aidan m collins  william hc chang  william hc chang  william hc chang  douglas murphychutorian  douglas murphychutorian  douglas murphychutorian  last  sell shares herbert j semler  herbert j semler  herbert j semler  herbert j semler  herbert j semler  herbert j semler  herbert j semler  herbert j semler  herbert j semler  herbert j semler    current  week ago  weeks ago  weeks ago high target price estimate     low target price estimate     mean target price estimate     standard deviation     date of most recent estimate     form type form description pages date k report of unscheduled material events or corporate changes   q quarterly report with a continuing view of a companys financial position   k report of unscheduled material events or corporate changes    statement of changes in beneficial ownership of securities   q quarterly report with a continuing view of a companys financial position   k report of unscheduled material events or corporate changes   k annual report with a comprehensive overview of the company   k report of unscheduled material events or corporate changes    initial statement of beneficial ownership of securities    statement of changes in beneficial ownership of securities     current  month ago  months ago  months ago strong buy     moderate buy     hold     moderate sell     strong sell     mean rec     news semler to report second quarter  financial results and host conference call on august   july     semler scientifics smlr ceo douglas murphychutorian on q  results  earnings call transcript may     semler scientific reports q results may     semler reports first quarter  financial results may     health care stocks aided by  gain by semler scientific inc smlr on april  april     semler to report first quarter  financial results and host conference call on may   april     semler scientific inc smlr gives up  at midday on march  pressuring health care stocks march     popular tweets  fetching no one is talking about this yet × you must log in first im sorry but in order to complete what youre trying to do you must be logged in take me to log in dont have an account im good for now corporate sitepremium productsadvertisingrss feeds aboutcontactsite maptestimonials privacy policyterms and conditionsdisclaimerconference   equities  all dates and time are being displayed in eastern standard time est